UKHSA has issued a further update on the invasive meningococcal disease outbreak centred on Canterbury, Kent. As at 12:30 on 21 March 2026, officials recorded 20 laboratory‑confirmed cases and 9 probable cases; two deaths have been reported. Nineteen of the 20 confirmed cases are MenB and all identified patients have been hospitalised. The figures were published on 22 March and remain subject to revision as investigations continue. (gov.uk)
The agency notes that the fall in confirmed cases since 20 March reflects reclassification after confirmatory testing and clinical assessment. Counts may move up or down as the Meningococcal Reference Unit in Manchester completes reference testing; daily figures are collated at 12:30 and released at 09:30 the following morning. (gov.uk)
Immediate control continues to prioritise a single course of prophylactic antibiotics for eligible groups. Distribution is in place at the University of Kent and through GP practices across England so students who have travelled home can access treatment; students who have returned, or will return, to Scotland are asked to contact their local NHS Board Health Protection Team. Advice remains to take antibiotics promptly if contacted, including people linked to the Club Chemistry exposure period first identified between 5 and 7 March. (gov.uk)
Vaccination is being used to provide longer‑term protection to those at elevated risk. The programme began with around 5,000 residents and staff in University of Kent halls of residence and, on 19 March, was extended to everyone who has been offered antibiotics as part of the response. The widened offer includes sixth‑form students (years 12–13) in affected schools and people who visited or worked at Club Chemistry between 5 and 15 March. UKHSA also confirmed that eligible individuals can obtain both antibiotics and the MenB vaccine via their local GP anywhere in England, and that 20,000 NHS doses will be released to the private market to ease short‑term supply pressures. (gov.uk)
Initial genomic analysis indicates the outbreak strain is meningococcal group B, sequence type ST‑485 within clonal complex ST‑41/44. UKHSA reports that the Bexsero vaccine being used should provide protection against this strain. To support wider scientific scrutiny, UKHSA has published identifiers for the sequenced genome (UKHSA 1926231; pubMLST 190637). (gov.uk)
Investigations have identified confirmed cases among students at four Kent schools and one student at a London higher education institution who is directly linked to the outbreak. An early exposure setting was the Canterbury nightclub Club Chemistry on 5 to 7 March, prompting targeted antibiotic clinics and outreach. (gov.uk)
For practical access, the Kent and Medway Integrated Care System is running antibiotic and vaccine clinics and provides live capacity updates. The ICS advises that eligible people who have left the area can be vaccinated by their GP, and that anyone with symptoms should attend A&E or call 999; emergency departments will not supply prophylaxis to people without symptoms. (kmhealthandcare.uk)
UKHSA stresses that antibiotics remain the most important immediate action in this incident, while vaccination offers longer‑term protection for those at increased risk. The assessed risk to the wider public remains low, but people should be alert to symptoms such as a sudden high fever, severe headache, stiff neck, vomiting or a non‑blanching rash and seek urgent medical attention. (gov.uk)
UKHSA is coordinating the response nationally to support surveillance and access to treatment. Officials have not declared a national NHS incident and normal NHS services continue to operate. (gov.uk)
Case totals and definitions are being refreshed daily. UKHSA commits to publishing updated outbreak counts at 09:30 each morning, based on figures recorded at 12:30 the previous day; eligibility criteria, clinic locations and operational updates are set out on the Kent and Medway ICS information hub. (gov.uk)